Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Adial Pharmaceuticals ( (ADIL) ) is now available.
On August 1, 2025, Adial Pharmaceuticals entered into a new sales agreement with A.G.P./Alliance Global Partners to sell its common stock through an at-the-market offering, replacing a previous agreement with H.C. Wainwright & Co., LLC. This strategic move allows Adial Pharmaceuticals to potentially raise up to $4,983,000, enhancing its financial flexibility and market presence, while the previous agreement had resulted in the sale of 2,348,520 shares for approximately $4,000,000.
The most recent analyst rating on (ADIL) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Adial Pharmaceuticals stock, see the ADIL Stock Forecast page.
Spark’s Take on ADIL Stock
According to Spark, TipRanks’ AI Analyst, ADIL is a Underperform.
Adial Pharmaceuticals’ overall stock score is low due to ongoing financial struggles, including a lack of revenue and reliance on external funding. Technical analysis provides no strong directional signal, and valuation metrics are weak due to negative earnings. However, the recent FDA approval for AD04 offers a positive strategic outlook, but this is not enough to counteract the financial and operational challenges currently faced.
To see Spark’s full report on ADIL stock, click here.
More about Adial Pharmaceuticals
Adial Pharmaceuticals, Inc. is a Delaware-based company operating in the pharmaceutical industry. The company focuses on the development and commercialization of therapeutic products, primarily targeting addiction and related disorders.
Average Trading Volume: 9,148,065
Technical Sentiment Signal: Sell
Current Market Cap: $6.88M
For a thorough assessment of ADIL stock, go to TipRanks’ Stock Analysis page.